Ikuo Nishimoto Appl. No. 10/088,699 Amdt. dated December 23, 2004 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Cancel)
- 2. (Currently amended) A method of screening for a disorder suppressor gene, wherein said method comprises the steps of:
- (a) expressing in a cell a nucleic acid obtained from or synthesized from a nucleic acid obtained from a tissue of an organism suffering from a disorder that accompanies cell death, wherein said tissue is obtained from an organ affected by showing cell death as a pathological feature of the disorder;
- (b) detecting a suppressive effect on the disorder due to the expression of the nucleic acid; and,
- (c) selecting the nucleic acid having the suppressive effect; thereby identifying a disorder suppressor gene.
- 3. (Withdrawn) A method of screening for a disorder suppressor polypeptide or a disorder suppressor gene encoding said polypeptide, wherein said method comprises the steps of:
- (a) administering to a cell (i) a polypeptide derived from a tissue of an organism suffering from a disorder that accompanies cell death, or (ii) a polypeptide encoded by a nucleic acid derived from said tissue, wherein said tissue is derived from an area affected by the disorder or from the vicinity of the affected area.

Ikuo Nishimoto Appl. No. 10/088,699 Amdt. dated December 23, 2004 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

- (b) detecting a suppressive effect on the disorder due to the expression of the nucleic acid, and,
 - (c) selecting the nucleic acid having the suppressive effect.
- 4. (Previously presented) The method according to claims 2, comprising the step of inducing the cell death associated with said disorder before, during or after step (a), and detecting the suppressive effect on the disorder in step (b) using the suppression of cell death as an index.
- 5. (Previously presented) The method according to claims 2, wherein said disorder is a disorder of the cranial nervous system.
- 6. (Original) The method according to claim 5, wherein said disorder of the cranial nervous system is Alzheimer's Disease.
- 7. (Previously presented) The method according to claim 5, wherein said nucleic acid is obtained from or synthesized from a nucleic acid obtained from a tissue of a nerve or brain.
- 8. (Currently amended) A method for testing a suppressive effect of a nucleic acid on a disorder, wherein said method comprises the steps of:
- (a) expressing in a cell a nucleic acid obtained from or synthesized from a nucleic acid obtained from a tissue of an organism suffering from a disorder that accompanies cell death, wherein said tissue is obtained from an organ affected by showing cell death as a pathological feature of the disorder, and,
- (b) detecting the suppressive effect on the disorder due to the expression of the nucleic acid;

Ikuo Nishimoto Appl. No. 10/088,699 Amdt. dated December 23, 2004 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

thereby identifying a suppressive effect of a nucleic acid on the disorder.

- 9. (Withdrawn) A method for testing a suppressive effect of a polypeptide on a disorder, wherein said method comprises the steps of:
- (a) administering to a cell (i) a polypeptide derived from a tissue of an organism suffering from a disorder that accompanies cell death, or (ii) a polypeptide encoded by a nucleic acid derived from said tissue, wherein said tissue is derived from an area affected by the disorder or from the vicinity of the affected area; and
- (b) detecting the suppressive effect on the disorder due to the administration of the polypeptide.
- 10. (Previously presented) The method according to claim 8, comprising the step of inducing the cell death associated with said disorder before, during or after step (a), and detecting the suppressive effect on the disorder in the step (b) using the suppression of cell death as an index.
- 11. (Previously presented) The method according to claim 8, wherein said disorder is a disorder of the cranial nervous system.
- 12. (Original) The method according to 11, wherein said disorder of the cranial nervous system is Alzheimer's Disease.
- 13. (Previously presented) The method according to claim 11, wherein said nucleic acid is obtained from or synthesized from a nucleic acid obtained from a tissue of a nerve or brain.
- 14. (Previously presented) The method according to claim 2, wherein said disorder is a neurodegenerative disease.

Ikuo Nishimoto Appl. No. 10/088,699

Amdt. dated December 23, 2004

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group

15. (Previously presented) The method according to claim 8, wherein said disorder is a neurodegenerative disease.

PATENT

- 16. (Currently amended) The method according to claim 2, wherein said tissue is obtained from an area of the organ affected by said disorder showing the cell death.
- 17. (Currently amended) The method according to claim 8, wherein said tissue is obtained from an area of the organ affected by said disorder showing the cell death.
- 18. (Previously presented) The method according to claim 2, wherein a plurality of nucleic acids that cause the suppressive effect are identified, further comprising:
- (d) cross-hybridizing the nucleic acids to each other to identify non-redundant groups.
- 19. (Previously presented) The method according to claim 8, wherein a plurality of nucleic acids that cause the suppressive effect are identified, further comprising:
- (d) cross-hybridizing the nucleic acids to each other to identify non-redundant groups.